Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease

Archaeosomes: an excellent carrier for drug and cell delivery

“…T. cruzi antigens can be incorporated successfully into ARC and, upon sc inoculation in mice, the resulting immunogen is capable of priming a protective response against an intracellular parasite infection. ARCs show promise as safe and helpful carrieradjuvant for the design of future vaccines against this human pathogen (Higa et al, 2013).…”

Nanomedical Therapeutic and Prophylaxis Strategies Against Intracellular Protozoa in the Americas

“…After subcutaneous administration in mice, archeosomes are potent adjuvants for the induction of Th1, Th2, and CD8 1 T-cell responses to the entrapped soluble Ag (Krishnan and Sprott, 2008). We showed that three administrations of archeosomes containing 12.5 μg of soluble T. cruzi proteins (days 0, 14, 21) in C3H/HeN mice generated higher levels of circulating antibodies than those measured in the sera from animals receiving the Ag alone, with a dominant IgG2a isotype associated with Th1-type immunity (Higa et al, 2013). Immunized mice displayed reduced parasitemia during infection and were protected against the lethal challenge (intraperitoneal administration of 150 trypomastigotes of Tulahuen strain; 100% survival of animals immunized with archeosomes at 30 dpi versus 100% mortality of control groups at 25 dpi).…”

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

“…Archaeal lipid adjuvants are a good potential candidate for use in combination with CPI's, as evidenced by their proven safety and efficacy in mice [19,44]. In multiple pre-clinical studies, they have been shown to activate antigen-specific CD8 + T cell responses [15,19,26,27] and generate protective immunity in tumor models, e.g., B16-OVA melanoma [7,13,19,23,26,27], and against multiple infectious diseases, e.g., H1N1 influenza [11], Listeria monocytogenes [7,12], Trypanosoma cruzi [13] and Mycobacterium tuberculosis [14]. When compared to commonly used commercial adjuvants, such as Poly(I:C) or Montanide, archaeal lipid vaccines were found to elicit equal or greater antigen specific CD8 + T cell-mediated cytotoxicity and IgG responses [10].…”

“…Archaeosomes have been consistently proven to be a versatile adjuvant capable of inducing potent immunity in a number of animal models of disease. To date, archaeosomes have been used with multiple antigens, including listeriolysin (LLO), tyrosinase-related-protein-2 (Trp2), glycoprotein-100 (Gp100), Hepatitis-B surface antigen (HBsAg), influenza haemagglutinin (HA) and Hepatitis-C virus E1E2 heterodimer (HCV E1E2) [7][8][9][10][11][12], inducing both strong antibody responses as well as potent cellular responses that afford protection against infections and/or tumor challenge in murine models [7,8,[12][13][14][15]. Archaeosomes are lipid vesicles composed of glycerolipids derived from archaea.…”